629 related articles for article (PubMed ID: 14678996)
1. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
2. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.
Dormond O; Foletti A; Paroz C; Rüegg C
Nat Med; 2001 Sep; 7(9):1041-7. PubMed ID: 11533708
[TBL] [Abstract][Full Text] [Related]
3. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
Sawaoka H; Tsuji S; Tsujii M; Gunawan ES; Sasaki Y; Kawano S; Hori M
Lab Invest; 1999 Dec; 79(12):1469-77. PubMed ID: 10616198
[TBL] [Abstract][Full Text] [Related]
5. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells.
Jiang WG; Hiscox SE; Parr C; Martin TA; Matsumoto K; Nakamura T; Mansel RE
Clin Cancer Res; 1999 Nov; 5(11):3695-703. PubMed ID: 10589789
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor beta2 inhibition of hepatocyte growth factor-induced endothelial proliferation and migration.
Manganini M; Maier JA
Oncogene; 2000 Jan; 19(1):124-33. PubMed ID: 10644987
[TBL] [Abstract][Full Text] [Related]
8. Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor.
Brzozowski T; Konturek PC; Konturek SJ; Pajdo R; Schuppan D; Drozdowicz D; Ptak A; Pawlik M; Nakamura T; Hahn EG
J Physiol Pharmacol; 2000 Dec; 51(4 Pt 1):751-73. PubMed ID: 11192947
[TBL] [Abstract][Full Text] [Related]
9. Nonsteroidal anti-inflammatory drugs may delay the repair of gastric mucosa by suppressing prostaglandin-mediated increase of hepatocyte growth factor production.
Bamba H; Ota S; Kato A; Matsuzaki F
Biochem Biophys Res Commun; 1998 Apr; 245(2):567-71. PubMed ID: 9571196
[TBL] [Abstract][Full Text] [Related]
10. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells.
Kuba K; Matsumoto K; Ohnishi K; Shiratsuchi T; Tanaka M; Nakamura T
Biochem Biophys Res Commun; 2000 Dec; 279(3):846-52. PubMed ID: 11162438
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.
Elder DJ; Halton DE; Hague A; Paraskeva C
Clin Cancer Res; 1997 Oct; 3(10):1679-83. PubMed ID: 9815550
[TBL] [Abstract][Full Text] [Related]
12. [Clinical application of cyclooxygenase-2 inhibitors].
Dzielska-Olczak M; Olczak S
Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2-mediated angiogenesis in carrageenin-induced granulation tissue in rats.
Ghosh AK; Hirasawa N; Niki H; Ohuchi K
J Pharmacol Exp Ther; 2000 Nov; 295(2):802-9. PubMed ID: 11046121
[TBL] [Abstract][Full Text] [Related]
14. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells.
Di Popolo A; Memoli A; Apicella A; Tuccillo C; di Palma A; Ricchi P; Acquaviva AM; Zarrilli R
Oncogene; 2000 Nov; 19(48):5517-24. PubMed ID: 11114729
[TBL] [Abstract][Full Text] [Related]
15. Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors.
Iñiguez MA; Punzón C; Fresno M
J Immunol; 1999 Jul; 163(1):111-9. PubMed ID: 10384106
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.
Fernández de Arriba A; Cavalcanti F; Miralles A; Bayón Y; Alonso A; Merlos M; García-Rafanell J; Forn J
Mol Pharmacol; 1999 Apr; 55(4):753-60. PubMed ID: 10101034
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.
Kurumbail RG; Stevens AM; Gierse JK; McDonald JJ; Stegeman RA; Pak JY; Gildehaus D; Miyashiro JM; Penning TD; Seibert K; Isakson PC; Stallings WC
Nature; 1996 Dec 19-26; 384(6610):644-8. PubMed ID: 8967954
[TBL] [Abstract][Full Text] [Related]
18. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
Dammann HG
Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis.
Montesano R; Soriano JV; Malinda KM; Ponce ML; Bafico A; Kleinman HK; Bottaro DP; Aaronson SA
Cell Growth Differ; 1998 May; 9(5):355-65. PubMed ID: 9607557
[TBL] [Abstract][Full Text] [Related]
20. Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators.
Kalgutkar AS; Kozak KR; Crews BC; Hochgesang GP; Marnett LJ
J Med Chem; 1998 Nov; 41(24):4800-18. PubMed ID: 9822550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
